iTeos is now developing EOS200271 which is a synthetic, small molecule inhibitor of indoleamine 2,3 - dioxygenase (IDO1), which has demonstrated the same anti-tumour activity in multiple preclinical tumour models in
combination with immune checkpoint inhibitors as competitors, but also has demonstrated superior brain penetration.
«Cancer treatment for transplant patients discovered: Letter notes combination of steroids and immunosuppressants,
combined with immune checkpoint inhibitors helps prevent organ rejection in kidney transplant patients undergoing cancer treatment.»
Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit — sometimes durable — from
treatment with immune checkpoint inhibitors that block the PD - 1 checkpoint, while other patients don't.
«These results confirm that antibiotics - associated dysbiosis might be deleterious in patients
treated with immune checkpoint inhibitors, suggesting that an intact gut microbiota is needed to mobilize the immune system regardless of the tumor site,» wrote Lisa Derosa, MD, of Gustave Roussy Cancer Campus, Villejuif, France, and colleagues.
When
combined with immune checkpoint inhibitors, an existing technology that amplifies T - cell tumor - fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice.
Dr. Jhaveri and Dr. Barnett observed during the treatment of a patient living with cancer who had a kidney transplant that the combination of steroids and sirolimus, an immunosuppressant that has anti-cancer properties, could prevent a patient's body from rejecting the organ during cancer
treatment with immune checkpoint inhibitors.
To create this model, researchers used data from melanoma and lung cancer patients being treated
with immune checkpoint inhibitors.
Patients in the study were treated
with immune checkpoint inhibitors that block the activation of PD1, a protein on immune system T cells that halts immune response.
The data presented provide new insights on the potential mechanism by which Seres» microbiome therapies could improve the outcomes of cancer patients treated
with immune checkpoint inhibitors.
The designation is specifically for patients with locally advanced or metastatic urothelial cancer who have previously been treated
with immune checkpoint inhibitors.
EOS200271 has demonstrated anti-tumor activity in multiple preclinical tumor models in monotherapy and in combination
with immune checkpoint inhibitors.
Gowans MF et al. (2018) Baseline antibody profiles predict toxicity in melanoma patients treated
with immune checkpoint inhibitors.
EOS200271 has demonstrated anti-tumour activity in multiple preclinical tumour models in combination
with immune checkpoint inhibitors.